ClinicalTrials.gg
RecruitingNCT06736327Updated May 8, 2026

A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors

A Phase 1 interventional study of SKB500 in Advanced Solid Tumors, sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study aims to evaluate the safety, tolerability, PK profile, immunogenicity, and antitumor activity of SKB500 in subjects with advanced solid tumors.

Read the detailed description

This study is a multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, PK profile, immunogenicity, and antitumor activity of SKB500 in subjects with advanced solid tumors. The study includes a dose-escalation phase, a dose-expansion phase, and an indication-expansion phase.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is the lead sponsor of 55 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants between 18 and 75 years old.
  2. or cytologically confirmed advanced solid tumors for which standard treatment either does not exist or has proven ineffective or intolerable.
  3. Subjects should ideally provide a tumor tissue sample for biomarker testing during the screening period.
  4. Has at least 1 according to (RECIST) Version 1.1
  5. performance status score of 0 or 1.
  6. Expected survival of at least 12 weeks.
  7. Has adequate hematopoietic, renal and hepatic functions.
  8. Have recovered to grade ≤ 1 of prior anti-cancer treatment toxicities.
  9. Male and female subjects must agree to use highly effective methods throughout the study.
  10. Subjects must voluntarily enter the study, sign the form, and be able to comply with the visits and procedures.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with known active , carcinomatous meningitis, , or spinal cord compression.
  2. Subjects with other within 5 years before the first dose.
  3. Any severe and/or uncontrolled concurrent disease that may interfere with the subject's participation in the study.
  4. Active , or ; active tuberculosis, or (HIV) test positive, or known acquired immunodeficiency syndrome (AIDS).
  5. History of allergy to any component of SKB500 or history of severe reactions to other monoclonal antibodies.
  6. Subjects with a history of interstitial lung disease, non-infectious pneumonia, or other pulmonary diseases significantly affecting lung function.
  7. History of allogeneic organ transplantation or hematopoietic stem cell transplantation.
  8. Uncontrolled pleural effusion, ascites, or pericardial effusion.
  9. Have received ADCs with the same target or the same toxins.
  10. Have received chemotherapy, small molecule targeted therapy, and traditional Chinese medicine preparations within 14 days or 5 half-lives before the first dose; have received any immunotherapy, large molecule anticancer drug treatment, or more than 30% bone marrow radiation or extensive radiotherapy within 28 days before the first dose.
  11. Have undergone major surgery or severe trauma within 28 days before the first dose.
  12. Have received other clinical trial medications within 28 days before the first dose.
  13. Has previously received anti-cancer or within 28 days before the first dose
  14. Have received systemic or other treatments within 14 days before the first dose.
  15. Have received potent inhibitors, inducers, or BCRP inhibitors within 14 days or 5 half-lives before the first dose.
  16. Pregnant or lactating female.
  17. Any disease or condition that, in the investigator's opinion, would compromise subject safety or interfere with study assessments.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    SKB500

    Subjects will receive SKB500 once every three weeks (Q3W).

    Drug: SKB500

Interventions

  • DrugSKB500

    The administration route of SKB500 is intravenous infusion, with a dosing frequency of Q3W.

06

What researchers measure

Primary outcomes

  1. Evaluate the incidence of adverse events (AEs)

    Time frame: Up to 3 years

  2. Evaluate the incidence of serious adverse events (SAEs)

    Time frame: Up to 3 years

  3. Evaluate the incidence of treatment related adverse events (TRAEs)

    Time frame: Up to 3 years

  4. Evaluate the incidence of dose-limiting toxicities (DLTs)

    Time frame: Day 1 to Day 21 in Cycle 1 in the dose escalation part

Secondary outcomes

  1. Investigate the antitumor activity of SKB500

    Time frame: Up to 3 years

  2. To evaluate the Tmax of SKB500

    Time frame: Up to 3 years

  3. To evaluate the Cmax of SKB500

    Time frame: Up to 3 years

  4. To evaluate the Cmin of SKB500

    Time frame: Up to 3 years

  5. To evaluate the AUC of SKB500

    Time frame: Up to 3 years

  6. To evaluate the t1/2 of SKB500

    Time frame: Up to 3 years

  7. To evaluate the CL of SKB500

    Time frame: Up to 3 years

  8. To evaluate the Vz of SKB500

    Time frame: Up to 3 years

  9. To evaluate the ADA of SKB500

    Time frame: Up to 3 years

Other outcomes

  1. To evaluate the relationship between the biomarker and the antitumor activity

    Time frame: Up to 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Jul 2027, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 16, 2024
StartActual
Dec 13, 2024
Primary completionEst.
Jul 31, 2027
CompletionEst.
Dec 31, 2028
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06736327
Responsible party
Sponsor
First posted
Dec 16, 2024
Start date
Dec 13, 2024
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
May 8, 2026

Study contacts

Yan Qing
Contact
qingyan@kelun.com
028-67255480

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SKB500

Start the discussion